المملكة المتحدة - الإنجليزية - myHealthbox

roche products limited - naproxen - tablets - 500 mg - anti-inflammatory and antirheumatic products, non-steroids - treatment of rheumatoid arthritis, osteoarthrosis (degenerative arthritis), ankylosing spondylitis, acute gout, acute musculoskeletal disorders and dysmenorrhoea.

المملكة المتحدة - الإنجليزية - myHealthbox

roche products limited - naproxen - tablets - 250mg - anti-inflammatory and antirheumatic products, non-steroids - treatment of rheumatoid arthritis, osteoarthrosis (degenerative arthritis), ankylosing spondylitis, acute gout, acute musculoskeletal disorders and dysmenorrhoea.

المملكة المتحدة - الإنجليزية - myHealthbox

roche products limited - naproxen - gastro-resistant tablets - 250mg - anti-inflammatory and antirheumatic products, non-steroids - it is indicated in adults for the treatment of rheumatoid arthritis, osteoarthrosis (degenerative arthritis), ankylosing spondylitis, acute musculoskeletal disorders (such as sprains and strains, direct trauma, lumbosacral pain, cervical spondylitis, tenosynovitis and fibrositis) and dysmenorrhoea.

المملكة المتحدة - الإنجليزية - myHealthbox

roche products limited - naproxen - gastro-resistant tablets - 375mg - anti-inflammatory and antirheumatic products, non-steroids - it is indicated in adults for the treatment of rheumatoid arthritis, osteoarthrosis (degenerative arthritis), ankylosing spondylitis, acute musculoskeletal disorders (such as sprains and strains, direct trauma, lumbosacral pain, cervical spondylitis, tenosynovitis and fibrositis) and dysmenorrhoea.

المملكة المتحدة - الإنجليزية - myHealthbox

roche products limited - naproxen - gastro-resistant tablets - 500mg - anti-inflammatory and antirheumatic products, non-steroids - it is indicated in adults for the treatment of rheumatoid arthritis, osteoarthrosis (degenerative arthritis), ankylosing spondylitis, acute musculoskeletal disorders (such as sprains and strains, direct trauma, lumbosacral pain, cervical spondylitis, tenosynovitis and fibrositis) and dysmenorrhoea.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 750 mg - tablet, modified release - excipient ingredients: sunset yellow fcf; hypromellose; purified water; magnesium stearate - rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and the relief of chronic pain states in which there is an inflammatory component.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

medical purchasing solutions, llc - cosyntropin (unii: 72yy86ea29) (cosyntropin - unii:72yy86ea29) - cortrosyn ® (cosyntropin) for injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see dosage and administrationsection). severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. for this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. when presumptive adrenal insufficiency is diagnosed by a subnormal cortrosyn ® test, further studies are indicated to determine if it is primary or secondary. primary adrenal insufficiency (addison’s disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. the production of adrenocortical hormones is deficient despite high acth levels (feedback mechanism). secondary or relative insufficiency arises as the result of defective production of acth leading in turn to disuse atrophy of the adrenal cortex. it is commonly seen, for example, as result of corticosteroid therapy, sheehan’s syndrome and pituitary tumors or ablation. the differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by acth whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with acth. patients selected for further study as the result of a subnormal cortrosyn ® test should be given a 3 or 4 day course of treatment with repository corticotropin injection usp and then retested. suggested doses are 40 usp units twice daily for 4 days or 60 usp units twice daily for 3 days. under these conditions little or no increase in plasma cortisol levels will be seen in addison’s disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency. the only contraindication to cortrosyn ® (cosyntropin) for injection is a history of a previous adverse reaction to it.

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

pfizer limited - tioconazole - nail solution - 283 mg/ml - imidazole and triazole derivatives

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - tioconazole - cutaneous solution - 283 milligram(s)/millilitre - imidazole and triazole derivatives; tioconazole

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - tioconazole - medicated nail lacquer - 283mg/1ml